ATE252561T1 - Chinolinderivate als mek enzym-inhibitoren - Google Patents

Chinolinderivate als mek enzym-inhibitoren

Info

Publication number: ATE252561T1
Authority: AT; Austria
Prior art keywords: alkyl; group; optionally; carbon; various
Prior art date: 1999-05-08

Application number

AT00927497T

Other languages

English (en)

Inventor

Keith Hopkinson Gibson

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-08

Filing date

2000-05-03

Publication date

2003-11-15

2000-05-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE252561T1 publication Critical patent/ATE252561T1/de

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
239000002532 enzyme inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
229910052799 carbon Inorganic materials 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000001246 bromo group Chemical group Br* 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
125000000962 organic group Chemical group 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
-1 pyimidinyl Chemical group 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Quinoline Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Enzymes And Modification Thereof (AREA)

AT00927497T 1999-05-08 2000-05-03 Chinolinderivate als mek enzym-inhibitoren ATE252561T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9910579.3A GB9910579D0 (en)	1999-05-08	1999-05-08	Chemical compounds
PCT/GB2000/001707 WO2000068200A1 (en)	1999-05-08	2000-05-03	Quinoline derivatives as inhibitors of mek enzymes

Publications (1)

Publication Number	Publication Date
ATE252561T1 true ATE252561T1 (de)	2003-11-15

Family

ID=10852988

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00927497T ATE252561T1 (de)	1999-05-08	2000-05-03	Chinolinderivate als mek enzym-inhibitoren

Country Status (17)

Country	Link
US (1)	US6809106B1 (de)
EP (1)	EP1178966B1 (de)
JP (1)	JP2002544195A (de)
KR (1)	KR20010110810A (de)
CN (1)	CN1352635A (de)
AT (1)	ATE252561T1 (de)
AU (1)	AU4589700A (de)
BR (1)	BR0010324A (de)
CA (1)	CA2370838A1 (de)
DE (1)	DE60006099T2 (de)
GB (1)	GB9910579D0 (de)
IL (1)	IL146326A0 (de)
NO (1)	NO20015446L (de)
NZ (1)	NZ514814A (de)
TR (1)	TR200103184T2 (de)
WO (1)	WO2000068200A1 (de)
ZA (1)	ZA200108965B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7067532B2 (en)	2000-11-02	2006-06-27	Astrazeneca	Substituted quinolines as antitumor agents
WO2002036570A1 (en)	2000-11-02	2002-05-10	Astrazeneca Ab	4-substituted quinolines as antitumor agents
GB0112834D0 (en)	2001-05-25	2001-07-18	Smithkline Beecham Plc	Medicaments
GB0215823D0 (en) *	2002-07-09	2002-08-14	Astrazeneca Ab	Quinazoline derivatives
GB0225579D0 (en) *	2002-11-02	2002-12-11	Astrazeneca Ab	Chemical compounds
ES2389258T3 (es) *	2003-06-17	2012-10-24	Millennium Pharmaceuticals, Inc.	Composiciones y métodos para inhibir TGF-s
US20050171182A1 (en) *	2003-12-11	2005-08-04	Roger Briesewitz	Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US20090239936A1 (en)	2006-05-15	2009-09-24	Yoshikazu Sugimoto	Prophylactic and Therapeutic Agent for Cancer
EP2069302B1 (de) *	2006-09-15	2010-08-25	Pfizer Inc.	Substituierte pyridylmethylbicyclocarboxyamidverbindungen
EP2481735A1 (de) *	2007-05-09	2012-08-01	Pfizer Inc.	Substituierte heterocyclische Derivate und Zusammensetzungen und ihre pharmazeutische Verwendung als antibakterielle Mittel
US9353122B2 (en)	2013-02-15	2016-05-31	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en)	2013-02-20	2016-05-31	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
KR20160099084A (ko)	2013-11-01	2016-08-19	칼라 파마슈티컬스, 인크.	치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
WO2015108907A2 (en)	2014-01-14	2015-07-23	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US20170248603A1 (en)	2014-10-06	2017-08-31	Dana-Farber Cancer Institute, Inc.	Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
CN104860869B (zh) *	2015-04-03	2017-11-03	北京大学	具有mek激酶抑制功能的化合物及其制备方法与应用
US20190008859A1 (en)	2015-08-21	2019-01-10	Acerta Pharma B.V.	Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
US20190112317A1 (en)	2015-10-05	2019-04-18	The Trustees Of Columbia University In The City Of New York	Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2018048750A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en)	2016-09-08	2019-04-09	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (de)	2016-09-08	2020-05-20	Kala Pharmaceuticals, Inc.	Kristalline formen therapeutischer verbindungen und verwendungen davon

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE317376B (de)	1961-07-10	1969-11-17	Roussel Uclaf
FR2077455A1 (en)	1969-09-03	1971-10-29	Aries Robert	5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3936461A (en)	1973-09-24	1976-02-03	Warner-Lambert Company	Substituted 4-benzylquinolines
FR2498187A1 (fr)	1981-01-16	1982-07-23	Rhone Poulenc Sante	Procede de preparation d'amino-4 chloro-7 quinoleines
IL81307A0 (en)	1986-01-23	1987-08-31	Union Carbide Agricult	Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US4743601A (en) *	1987-07-13	1988-05-10	Hoechst-Roussel Pharmaceuticals Inc.	Dihydro-1,4-oxazino(2,3-C)quinolines
IL89029A (en) *	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
DE69222637T2 (de)	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2114727C (en)	1991-08-02	1996-12-10	Mikel P. Moyer	Quinoline derivatives as immunostimulants
US5656643A (en)	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
US5650415A (en)	1995-06-07	1997-07-22	Sugen, Inc.	Quinoline compounds
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
DE69622183D1 (de)	1995-11-07	2002-08-08	Kirin Brewery	Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
US6391874B1 (en)	1996-07-13	2002-05-21	Smithkline Beecham Corporation	Fused heterocyclic compounds as protein tyrosine kinase inhibitors
CN1252054C (zh)	1996-09-25	2006-04-19	曾尼卡有限公司	抑制生长因子的作用的喹啉衍生物
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
UA73073C2 (uk) *	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ES2229515T3 (es) *	1997-07-01	2005-04-16	Warner-Lambert Company Llc	Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
ATE344791T1 (de) *	1997-07-01	2006-11-15	Warner Lambert Co	2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
US6310060B1 (en) *	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
RS49779B (sr)	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
HU230728B1 (hu)	1998-09-29	2017-12-28	Wyeth Holdings Llc	Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
CZ303899B6 (cs)	1998-09-29	2013-06-19	Wyeth Holdings Corporation	Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem

1999
- 1999-05-08 GB GBGB9910579.3A patent/GB9910579D0/en not_active Ceased
2000
- 2000-05-03 AU AU45897/00A patent/AU4589700A/en not_active Abandoned
- 2000-05-03 WO PCT/GB2000/001707 patent/WO2000068200A1/en not_active Ceased
- 2000-05-03 TR TR2001/03184T patent/TR200103184T2/xx unknown
- 2000-05-03 KR KR1020017014190A patent/KR20010110810A/ko not_active Withdrawn
- 2000-05-03 DE DE60006099T patent/DE60006099T2/de not_active Expired - Fee Related
- 2000-05-03 CN CN00807282A patent/CN1352635A/zh active Pending
- 2000-05-03 CA CA002370838A patent/CA2370838A1/en not_active Abandoned
- 2000-05-03 NZ NZ514814A patent/NZ514814A/en unknown
- 2000-05-03 EP EP00927497A patent/EP1178966B1/de not_active Expired - Lifetime
- 2000-05-03 JP JP2000617180A patent/JP2002544195A/ja active Pending
- 2000-05-03 US US09/959,005 patent/US6809106B1/en not_active Expired - Fee Related
- 2000-05-03 BR BR0010324-1A patent/BR0010324A/pt not_active IP Right Cessation
- 2000-05-03 IL IL14632600A patent/IL146326A0/xx unknown
- 2000-05-03 AT AT00927497T patent/ATE252561T1/de not_active IP Right Cessation
2001
- 2001-10-30 ZA ZA200108965A patent/ZA200108965B/en unknown
- 2001-11-07 NO NO20015446A patent/NO20015446L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1352635A (zh)	2002-06-05
EP1178966A1 (de)	2002-02-13
NZ514814A (en)	2003-10-31
WO2000068200A1 (en)	2000-11-16
TR200103184T2 (tr)	2002-03-21
NO20015446D0 (no)	2001-11-07
AU4589700A (en)	2000-11-21
DE60006099T2 (de)	2004-07-08
ZA200108965B (en)	2003-01-30
JP2002544195A (ja)	2002-12-24
US6809106B1 (en)	2004-10-26
IL146326A0 (en)	2002-07-25
GB9910579D0 (en)	1999-07-07
BR0010324A (pt)	2002-01-08
EP1178966B1 (de)	2003-10-22
DE60006099D1 (de)	2003-11-27
NO20015446L (no)	2001-12-12
KR20010110810A (ko)	2001-12-13
CA2370838A1 (en)	2000-11-16

Legal Events

Date	Code	Title	Description
2004-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60006099D1 (de)	2003-11-27	Chinolinderivate als mek enzym-inhibitoren
ATE250582T1 (de)	2003-10-15	Chinolinderivate als mek enzym-inhibitoren
NO20015448L (no)	2002-01-07	Kinolinderivater som inhibitorer av MEK-enzymer
AU572405B2 (en)	1988-05-05	Heterocyclic-substituted indole
HUP0104816A2 (hu)	2002-04-29	3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra
HK5684A (en)	1984-01-20	Penicillin derivatives
FI942635A0 (fi)	1994-06-03	Piperatsiinijohdannaiset 5HT1A-antagonisteina
MY140725A (en)	2010-01-15	New pyridazin-3(2h)-one derivatives
PE20050371A1 (es)	2005-08-17	Inhibidores de la caspasa conteniendo anillo isoxazolinico
PT887344E (pt)	2004-02-27	Quinolinas e quinazolinas uteis em terapia
HUP9903836A2 (hu)	2001-05-28	Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására
IL98681A (en)	1997-06-10	Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE60239170D1 (de)	2011-03-24	Bicyclische Verbindungen
FI914910A0 (fi)	1991-10-17	Heterocykliska foereningar.
FI913565A0 (fi)	1991-07-25	Substituerade fenylacetylenfoereningar, laekemedel innehaollande dem samt ett foerfarande foer framstaellning av dessa foereningar och laekemedel.
NO933478L (no)	1994-04-05	6-heterocyklisk-4-amino-1,2,2a,3,4,5-heksahydrobenz(CD)indoler for behandling av reisesyke og oppkast
MX9708422A (es)	1998-02-28	Esteres de carbapenemas.
PT74196B (en)	1984-01-05	Process for preparing ketohydroxyiminocephalosporins